Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke

Table 5 Logistic regression analysis of predictors for combined MANE on Day 90 after ischemic stroke

Variables	Odds Ratio	95% CI	P- value
Univariate
Systolic blood pressure*	0.978	0.960 to 0.996	0.017
Diastolic blood pressure*	0.962	0.931 to 0.994	0.019
Total cholesterol level	1.012	1.003 to 1.021	0.006
Low-density lipoprotein	1.013	1.003 to 1.022	0.010
EPO therapy	0.347	0.168 to 0.717	0.004
KDR/CD34	0.609	0.373 to 0.995	0.048
Multiple Stepwise
Total cholesterol level	1.012	1.003 to 1.021	0.010
Systolic blood pressure*	0.979	0.960 to 0.998	0.031
KDR/CD34	0.583	0.341 to 0.997	0.049
EPO therapy	0.334	0.153 to 0.730	0.006

CI, confidence interval; EPO, erythropoietin.
MANE, major adverse neurological event (defined as NIHSS ≥8, recurrent stroke or death on day 90 after acute IS); NIHSS, national institutes of health stroke scale.
* Indicates the continuity of systolic and diastolic blood pressure to be used for statistical analysis but not the history of hypertension.

ISSN: 1364-8535